Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)

NCT00599131 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped The study was discontinued prematurely due to early stopping rules.

Conditions

Cancer of Larynx

Interventions

DRUG: Cisplatin
DRUG: Cetuximab
DRUG: 5-Fluorouracil
DRUG: Docetaxel

Sponsor

University of Michigan Rogel Cancer Center